
Phase 2 data suggest FcRn blockade may reduce maternal IgG and placental antibody transfer in HDFN without excess infant infections.
Kenneth J. Moise Jr., MD
Professor, Department of Women's Health
Co-Director, Comprehensive Fetal Care Center
University of Texas at Austin Dell Medical School

Phase 2 data suggest FcRn blockade may reduce maternal IgG and placental antibody transfer in HDFN without excess infant infections.